Monitor future Form 4 filings for insider transactions and the company's next quarterly report for post-merger financials. The option grant is standard for a new CEO and does not signal any near-term catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $18.60entry
- T+1 · 20h ago +6.83%α +8.74% · $19.87
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Gregory Divis filed a Form 3 initial statement of beneficial ownership after becoming President and CEO of InMed Pharmaceuticals Inc. (now Mentari Therapeutics Inc.) following a merger. The filing discloses options to purchase 1,454,398 shares at $10.37, vesting over three years. This is a routine Section 16 filing with no material price impact.
Key Facts
- Gregory Divis appointed President and CEO of InMed Pharmaceuticals Inc. (now Mentari Therapeutics Inc.)
- Filing is an initial statement of beneficial ownership (Form 3) under Section 16(a)
- Divis holds stock options to buy 1,454,398 shares at $10.36 per share
- Options vest 25% on July 20, 2027 and monthly thereafter through July 20, 2030
- Filing relates to a merger effective November 6, 2026 involving Indigo Merger Sub Corp. and Pre-Merger Mentari
Financial Impact
No cash transaction; options valued at $10.36 strike price per share, vesting over ~3.7 years
Risk Factors
- No financial data in filing to assess company performance
- Merger integration risks not addressed in this filing
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-458265 |
| Document: 0001193125-26-458265-index-headers.html | 0001193125-26-458265 |
| Document: 0001193125-26-458265-index.html | 0001193125-26-458265 |
| Document: 0001193125-26-458265.txt | 0001193125-26-458265 |
Track record
10 reports on MTRI
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $17.90 Now $19.87 −11.01% settles Dec 15
- Nov 16, 2026today 8-K Neutral 6/10 Entry $18.60 Now $19.87 +6.83% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $19.02 Now $19.87 +4.47% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $15.75 Now $19.87 +26.16% settles Dec 15
- Nov 12, 20264d ago SC 13D Neutral 5/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Viewing Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 10, 20266d ago 8-K Mixed 7/10 Entry $15.61 Now $19.87 +27.30% settles Dec 10
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers